NEW YORK (AP) -- La Jolla Pharmaceutical Co. shares dropped Wednesday morning after an analyst began covering the stock with a “Sell” rating, predicting the company’s lupus drug candidate will fail a late-stage trial.
NEW YORK (AP) -- La Jolla Pharmaceutical Co. shares dropped Wednesday morning after an analyst began covering the stock with a “Sell” rating, predicting the company’s lupus drug candidate will fail a late-stage trial.
